Wegovy is a registered trademark of Novo Nordisk A/S. It is an FDA-approved prescription medicine. Medicare coverage is not the same for every prescribed use or every beneficiary.
Important safety information: Wegovy carries a boxed warning for the risk of thyroid C-cell tumors. It must not be used by people with a personal or family history of medullary thyroid carcinoma, or MTC, or by people with Multiple Endocrine Neoplasia syndrome type 2, or MEN 2. Serious risks include pancreatitis, gallbladder disease, hypoglycemia with certain diabetes medicines, kidney injury from dehydration, severe stomach problems, serious allergic reactions, diabetic retinopathy complications, increased heart rate, and pulmonary aspiration during anesthesia or deep sedation. Common side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain. Review the full official Prescribing Information and Medication Guide. A licensed clinician should assess both risks and potential benefits for the individual.
There are two coverage paths to understand in 2026. One is the regular Medicare Part D benefit for a coverable indication. The other is the temporary Medicare GLP-1 Bridge for eligible weight-management use. The rules do not let a person choose whichever route seems cheaper.
This page is general information, not medical advice. Talk to a licensed clinician about your situation.
Medicare looks at why it was prescribed
Part D has historically excluded medicines when used only for weight loss. Wegovy also has uses beyond weight management, so a plan must consider the indication attached to the prescription and clinical request.
Its FDA labeling includes reducing the risk of major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. CMS identifies that cardiovascular use as one that may be handled through the regular Part D benefit.
A Part D plan may still require prior authorization. It may check the diagnosis, clinical records, prescribed form, and pharmacy. It may also apply quantity limits or other formulary rules. Only the plan's final coverage decision establishes whether it will pay a claim.
If the drug is not on the formulary, or a coverage rule is not met, the member or prescriber can ask the plan for an exception. The Medicare drug-plan rules explain that a prescriber generally needs to provide a supporting medical statement. The plan decides the request.
How the 2026 Bridge differs
The Medicare GLP-1 Bridge began July 1, 2026, and is scheduled to operate through December 31, 2027. It is a nationwide, temporary demonstration for certain adults with Medicare drug coverage who meet specific clinical requirements.
According to Medicare's official Bridge overview, Wegovy injection and tablets are eligible products. The person must have a qualifying type of Part D coverage. A provider must prescribe the medicine for weight management with continuing lifestyle changes and complete prior authorization when requested.
Clinical eligibility can depend on body mass index and the presence of certain health conditions. The rules also exclude some people whose prescription belongs under regular Part D coverage. For example, a prescription intended to reduce major cardiovascular events should go to the Part D plan, even if the person could appear to meet Bridge criteria.
Current CMS terms set a $50 monthly medication copay under the Bridge for an eligible beneficiary. This is not a Body Good service fee. It is not a universal Wegovy price, and it does not apply unless the processor confirms eligibility. CMS states that this payment does not count toward the member's Part D true out-of-pocket costs.
A simple way to identify the route
First, confirm that the person has Medicare drug coverage. Original Medicare without a standalone drug plan does not by itself supply Part D benefits. Many Medicare Advantage plans include drug coverage, but plan type matters.
Second, ask the prescriber which labeled indication supports the prescription. This is a clinical question, not a wording choice made to obtain payment.
Third, call the plan. Ask whether the request goes through the plan's Part D prior authorization or the Bridge's central processor. The pharmacy may also see routing information when it submits the claim.
Fourth, request the expected cost in writing when possible. Ask whether the amount includes a deductible, copay, or coinsurance and whether the pharmacy is in network.
Finally, do not assume that last year's result applies this year. Formularies, utilization rules, and Medicare programs can change. Recheck after a plan change, a new benefit year, a different prescription, or a move to another pharmacy.
What Medicare does not decide for Body Good
Body Good offers a separate clinical service. Its $139 per month price is a Body Good service fee for the program described during intake. It is not a medication price and not a quote for any individual. Eligibility is determined by a clinician.
Medication cost is separate and not included in the Body Good service fee. The dispensing pharmacy or another authorized provider charges for medication. A Medicare decision about the prescription does not promise payment for Body Good's fee.
Keep each charge on its own line: the Body Good service fee, the pharmacy medication charge, and any outside laboratory cost. This prevents a Medicare medication copay from being mistaken for the full cost of clinical care.
Coverage support without promises
Body Good can assist with benefit checks, prior authorization paperwork, and clinical information requested by a plan or program. It can also provide follow-up care when someone joins the program.
This assistance does not secure coverage. Approval and payment are determined by the plan, Medicare, or the Bridge processor. A licensed clinician also decides whether any prescription is appropriate after evaluating the person.
This site provides informational and pricing overviews only. It takes no payment, collects no protected health information, and runs no intake form. Intake and checkout happen on joinbodygood.com.
Frequently asked questions
Is Wegovy automatically covered for everyone with Medicare?
No. The prescribed indication, type of drug coverage, plan rules, and Bridge eligibility can all matter. Medicare, the plan, or the relevant processor reviews the request.
Is the Medicare GLP-1 Bridge part of the normal Part D benefit?
No. CMS says the temporary Bridge operates outside the regular Part D payment flow. A prescription for a Part D-coverable indication should continue through the Part D plan.
Can Body Good help with a Medicare request?
Body Good can provide coverage support and assist with requested documentation. It cannot guarantee the decision or amount. Begin Body Good's secure clinical intake to provide information for review.
Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Body Good is not affiliated with, endorsed by, sponsored by, or authorized by Eli Lilly and Company or Novo Nordisk A/S. All trademarks are the property of their respective owners.